Health Care & Life Sciences » Biotechnology | Mateon Therapeutics Inc.

Mateon Therapeutics Inc.

Mateon Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.07
Market Cap
$8.08 M
Shares Outstanding
82.1 M
Public Float
40.21 M

Profile

Address
701 Gateway Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.mateon.com
Updated 07/08/2019
Mateon Therapeutics, Inc. operates as a clinical stage biopharmaceutical company which develops small molecule injectable drugs for the treatment of cancer. The firm develops OXi4503 for the treatment of acute myeloid leukemia. The OXi4503 has dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction.

Financials

View All
Created with Highcharts 5.0.14Mateon Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.8 2778 27712 64712 64713 65413 65413 65413 65413 81213 8122 7372 73720132014201520162017201802.5k5k7.5k10k12.5k15k
Created with Highcharts 5.0.14Mateon Therapeutics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.959500000000222013201420152016201720180255075100

William D. Schwieterman
Chairman, President & Chief Executive Officer
Bobby W. Sandage
Independent Director